文献速递浆细胞疾病

伊沙妥昔单抗皮下给药(穿戴式注射器)对比静脉给药联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤:III期IRAKLIA研究

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
PubMed 文献 · J Clin Oncol · 2025-06-03

IRAKLIA是一项多中心、开放标签III期试验,将531例复发/难治性多发性骨髓瘤患者随机分配至伊沙妥昔单抗皮下给药(穿戴式注射器,n=263)或静脉给药(n=268),联合泊马度胺和地塞米松。中位随访12个月,总缓解率分别为71.1%和70.5%,相对风险1.008(95%CI 0.903-1.126),达到非劣效;Ctrough几何均值比1.532(90%CI 1.316-1.784),亦达到非劣效。两组安全性可比,皮下组输注反应发生率更低。

要点

  • 皮下给药组总缓解率71.1% vs 静脉组70.5%,达到非劣效。
  • 皮下给药组Ctrough几何均值比1.532(90%CI 1.316-1.784),达到非劣效。
  • 皮下给药组输注反应发生率1.5% vs 静脉组25.0%,注射部位反应仅0.4%(均为1-2级)。

核心结论

  • IRAKLIA研究表明伊沙妥昔单抗皮下给药(穿戴式注射器)与静脉给药在疗效和药代动力学上均达到非劣效。
  • 未观察到非预期安全性信号,皮下给药局部耐受性良好。
  • 除皮下给药组输注反应发生率更低外,疗效和安全性可与ICARIA-MM中的伊沙妥昔单抗静脉给药相比。
  • 这些结果支持穿戴式注射器的潜在使用,旨在提高实践效率。

研究设计与样本

  • 多中心、开放标签III期IRAKLIA试验(ClinicalTrials.gov标识符NCT05405166)。
  • 纳入既往至少接受过1线治疗的患者,按1:1随机分配至伊沙妥昔单抗皮下给药(穿戴式注射器,1400 mg)或静脉给药(10 mg/kg)组。
  • 伊沙妥昔单抗第1周期每周一次,之后每2周一次,联合泊马度胺(4 mg每日一次,第1-21天)和地塞米松(40 mg每周一次;年龄≥75岁者20 mg),治疗至疾病进展、不可接受的毒性或患者要求。
  • 共随机分配531例患者(皮下给药组n=263;静脉给药组n=268)。
  • 共同主要终点为总缓解率(非劣效界值0.839)和伊沙妥昔单抗Ctrough(第6周期第1天给药前;非劣效界值0.8)。

主要发现

  • 中位随访12个月,总缓解率皮下给药组71.1% vs 静脉给药组70.5%,相对风险1.008(95%CI 0.903-1.126),置信区间下限超过非劣效界值。
  • 第6周期第1天Ctrough均值(标准差)皮下给药组499(259)μg/mL vs 静脉给药组340(169)μg/mL。
  • Ctrough几何均值比(90%CI)为1.532(1.316-1.784),置信区间下限超过非劣效界值。
  • ≥3级治疗中出现的不良事件发生率皮下给药组81.7% vs 静脉给药组76.1%;输注反应发生率分别为1.5%和25.0%。
  • 注射部位反应发生于0.4%的皮下注射中(均为1-2级);99.9%的注射无中断完成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the results of the multicenter, open-label IRAKLIA trial (ClinicalTrials.gov identifier: NCT05405166) of isatuximab subcutaneous (SC) versus intravenous (IV), plus pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma (MM), to our knowledge, the first phase III MM trial using an on-body injector (OBI). METHODS: Patients with ≥1 prior line of therapy were randomly assigned 1:1 to Isa OBI (1,400 mg) or IV (10 mg/kg) once weekly in cycle (C)1 and then every 2 weeks, plus pomalidomide (4 mg once daily, day [D]1-21) and dexamethasone (40 mg once weekly [age ≥75: 20 mg]) and treated until progression, unacceptable toxicity, or patient request. Coprimary end points were overall response rate (ORR; noninferiority margin, 0.839) and Isa Ctrough (C6D1 predose; noninferiority margin, 0.8). Noninferiority of OBI versus IV was demonstrated if both coprimary end points achieved noninferiority. RESULTS: IRAKLIA randomly assigned 531 patients (OBI, n=263; IV, n=268). After 12-month median follow-up, the ORR was 71.1% (OBI) and 70.5% (IV; relative risk, 1.008 [95% CI, 0.903 to 1.126]; lower CI exceeded noninferiority margin). The mean (standard deviation) C6D1 Ctrough was 499 (259) μg/mL (OBI) and 340 (169) μg/mL (IV). The Ctrough geometric mean ratio (90% CI) was 1.532 (1.316 to 1.784); lower CI exceeded noninferiority margin. Grade ≥3 treatment-emergent adverse event incidences were 81.7% (OBI) and 76.1% (IV); infusion reaction incidences were 1.5% and 25.0%. Injection site reactions occurred in 0.4% of OBI injections (all grade 1-2); 99.9% of injections completed without interruption. CONCLUSION: IRAKLIA demonstrated efficacy and pharmacokinetic noninferiority between Isa OBI and IV. No unexpected safety signal was observed, with excellent local tolerability of Isa OBI. Efficacy and safety were comparable with Isa IV in ICARIA-MM, except the lower OBI infusion reaction rate. These results support potential use of the OBI, designed to improve practice efficiency.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ailawadhi S, Špička I, Spencer A, et al. Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study. J Clin Oncol. 2025. PMID: 40459178. doi:10.1200/JCO-25-00744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。